Skip to content

Novartis’ Patrick Mooney Gives Inside Look on the Impact of Alcon Spin-Out, Bid to Acquire Xiidra

What Are Novartis’ Plans for Xiidra?

Episode 219

Patrick Mooney, head of Novartis’ US eye care business, lays out Novartis’ plans following the spin-out of Alcon and bid to acquire the former Shire ophthalmology franchise from Takeda. Where does Novartis see future growth in eye care? Will ophthalmologists and optometrists see a difference? Is Novartis done acquiring products for a while?

Do You Have

A STORY TO TELL?

If you’d like to be considered as a guest on a future episode of the OIS podcast, please complete the application today.

Meet Our New Host

EHSAN SADRI

Sadri_Ehsan

Joining the company in 2019, to create and manage a new line of podcasts, publications, and other editorial products.

Subscribe

ON iTUNES

Don't miss an episode. Join the conversation by visiting our podcast channel on iTunes today and subscribe. It's fast and free!

STAY UP TO DATE WITH OIS

Get the Latest News, Podcasts and Videos.

Scroll To Top